Cure My Disease

Don't miss your cure!

 Log in / Sign up

Timing of local therapy may boost immunotherapy in Hard-to-Treat esophageal cancer

NCT ID NCT07697859

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study investigates whether starting local treatments like radiation or surgery early or later alongside immunotherapy improves outcomes for people with esophageal cancer that has spread to a limited number of spots. Participants receive standard chemoimmunotherapy plus local therapy either within the first two cycles or after four cycles. The goal is to find the best sequence to extend life and control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PD-1 inhibitor (immunotherapy) combined with local therapy (radiotherapy, surgery, or ablation)
What this could lead to
If successful, this could establish the best timing for adding local therapy to immunotherapy, potentially improving survival and quality of life for people with oligometastatic esophageal cancer.
What could go wrong
This is a phase III trial, but the optimal timing remains unknown, and results may not apply to all patients. Risks include side effects from both immunotherapy and local treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan University Shanghai cancer center

    RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.